By Colin Kellaher
Stoke Therapeutics' chief executive, Edward Kaye, is stepping down after more than seven years at the helm of the biotechnology company.
Stoke on Tuesday said Ian Smith, a board member since September 2023, will step in as interim CEO, adding that it has launched a search for a permanent replacement for Kaye.
The Bedford, Mass., company said its chairman, Arthur Tzianabos, will serve as interim executive chairman and lead the CEO search.
Stoke said Kaye, who joined the company as CEO and a director in October 2017, will continue to serve as an adviser and non-executive board member.
The company said Kaye, 75 years old, will be entitled to receive payment of his current annual salary of $680,214 for 12 months, and that his existing equity awards will continue to vest as long as he is providing services as a board member or as an adviser.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 18, 2025 07:22 ET (11:22 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.